<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01738035</url>
  </required_header>
  <id_info>
    <org_study_id>Nef-202</org_study_id>
    <secondary_id>2012-001923-11</secondary_id>
    <nct_id>NCT01738035</nct_id>
  </id_info>
  <brief_title>The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease</brief_title>
  <acronym>NEFIGAN</acronym>
  <official_title>A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calliditas Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calliditas Therapeutics AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate efficacy and safety of two different doses of
      NEFECON in the treatment of patients with primary IgA nephropathy (IgAN) at risk of
      developing end-stage renal disease, under rigorous blood pressure control with an
      angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin II receptor I blocker
      (ARB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NEFECON is an add-on treatment to other medications for nephropathy symptoms and kidney
      function, including ACEI and/or ARBs. Rigorous blood pressure control will be achieved over a
      6-month Run-in Phase in which ACEI and/or ARB will be dosed to target a blood pressure of
      &lt;130/80 mm Hg and UPCR &lt;0.5 g/g. Patients who complete the Run-in Phase, and despite
      optimized ACEI and/or ARB therapy, have a UPCR ≥0.5 g/g OR urine protein ≥0.75 g/24hr will be
      eligible for randomization and entry into the treatment phase of the trial. Patients will
      remain on their ACEI and/or ARB dosing regimen for the duration of the trial.

      Patients entering the treatment phase will be administered NEFECON (8 mg/day OR 16 mg/day) OR
      placebo for a phase of 9 months. A 3-month follow-up phase will follow on from the treatment
      phase, of which the first 2 weeks will be used to taper the dose of those patients that
      received 16 mg/day dosing to 8 mg/day, with the placebo and 8 mg/day groups receiving placebo
      to retain blinding.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in urine protein creatinine ratio</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine albumin creatinine ratio</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24 hour albuminuria</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in estimated GFR</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in urine protein creatinine ratio</measure>
    <time_frame>3-12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in urine albumin creatinine ratio</measure>
    <time_frame>3-12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in 24 hour albuminuria</measure>
    <time_frame>3-12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in estimated GFR</measure>
    <time_frame>3-12 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Primary IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>NEFECON 8 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NEFECON 8 mg/day (2 active + 2 placebo capsules daily) for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NEFECON 16 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NEFECON 16 mg/day (4 active capsules daily) for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (4 placebo capsules daily) for 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEFECON</intervention_name>
    <description>All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.</description>
    <arm_group_label>NEFECON 8 mg/day</arm_group_label>
    <arm_group_label>NEFECON 16 mg/day</arm_group_label>
    <other_name>Budesonide modified-released capsules (4 mg/capsule)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening Inclusion Criteria:

          1. Female or male patients ≥18 years

          2. Biopsy-verified IgA nephropathy

          3. Urine protein creatinine ratio ≥0.5 g/g OR urine protein ≥0.75 g/24hr

          4. Estimated GFR (using the CKD-EPI formula) OR measured GFR ≥50 mL/min per 1.73 m2 OR
             ≥45 mL/min per 1.73m2 for patients on a maximum recommended or maximum tolerated dose
             of an ACEI and/or ARB

          5. Willing to change antihypertensive medication regimen if applicable

          6. Willing and able to give informed consent

        Screening Exclusion Criteria:

          1. Secondary forms of IgA nephropathy as defined by the treating physician (for example,
             Henoch-Schönlein purpura patients and those with associated alcoholic cirrhosis)

          2. Presence of crescent formation in ≥50% of glomeruli assessed on renal biopsy

          3. Kidney transplanted patients 4. Severe gastrointestinal disorders (including peptic
             ulcer disease and inflammatory bowel disease) which may impair drug effect, or other
             conditions which could modify the effect of the trial drug as judged by the
             Investigator

          4. Patients currently treated with systemic immunosuppressive or systemic corticosteroid
             drugs (excluding topical or nasal steroids) or have been previously treated for more
             than one week within the last 24 months.

          5. Patients currently treated chronically (daily dosing) with inhaled corticosteroid
             drugs or have previously been treated chronically for more than one month within the
             last 12 months

          6. Patients previously treated with immunosuppressive or systemic corticosteroids for the
             treatment of IgA nephropathy

          7. Patients unable to take oral medication or intolerant to budesonide or other
             corticosteroid preparations

          8. Patients with known allergy or intolerance to ACEI, ARB or to any component of the
             trial drug formulation

          9. Patients with acute or chronic infectious disease incl. hepatitis, HIV positive
             patients and patients with chronic urinary tract infections

         10. Severe liver disease according to the discretion of the Investigator

         11. Patients with Type 1 or 2 diabetes

         12. Patients with uncontrolled cardiovascular disease as judged by the Investigator

         13. Patients with current malignancy or history of malignancy during the last three years

         14. For women only; pregnant or breast feeding or unwilling to use adequate contraception
             during the trial (only women of child bearing potential)

        Randomization Inclusion Criteria:

          1. Completion of the Run-in Phase

          2. Urine protein creatinine ratio ≥0.5 g/g OR urine protein ≥0.75 g/24hr

          3. eGFR ≥45 mL/min per 1.73 m2 using CKD-EPI formula OR measured GFR ≥45 mL/min per 1.73
             m2

        Randomization Exclusion Criteria:

          1. Unacceptable blood pressure defined as a systolic value &gt;160 mm Hg or diastolic &gt;100
             mm Hg

          2. eGFR (CKD-EPI) loss &gt;30% over the entire duration of the Run-in Phase

          3. For women only; pregnant or breast feeding or unwilling to use adequate contraception
             during the trial (only women of child bearing potential)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bengt Fellström, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine Department of Medical Sciences, Renal Medicine Uppsala University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alex Mercer, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmalink AB, Stockholm, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heilig Hartziekenhuis Roeselare-Menen</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University &amp; General University Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut klinické a experimentální medicíny</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Hospital</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité-Virchow Clinic</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum-Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Karlstrasse</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsche Klinik für Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Würzburg University Hospital</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Brotzu</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A Manzoni</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bassini Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. G. Bosco</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belcolle Hospital</name>
      <address>
        <city>Viterbo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Puigver</name>
      <address>
        <city>Barcellona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcellona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>12 de Octubre Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Diaz Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central sjukhuset</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karlstad Central Hospital</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyds Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulster Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>November 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IgA nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

